Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180719 | 0.81 | CYP17A1 (0.52) | CYP17A1HTR2CSLC6A3SLC6A2SLC6A4 | |
| SCHEMBL24372431 | 0.81 | CYP17A1 (0.49) | CYP17A1SLC6A3SLC6A2SLC6A4RIPK1 | |
| SCHEMBL1180224 | 0.76 | CYP17A1 (0.47) | CYP17A1IDO1TDO2 | |
| SCHEMBL5569845 | 0.75 | CYP17A1 (0.41) | CYP17A1RORCALDH1A1 | |
| SCHEMBL1180760 | 0.73 | CYP17A1 (0.42) | CYP17A1CYP19A1 | |
| SCHEMBL5569832 | 0.73 | DRD2 (0.48) | CYP17A1CYP2D6 | |
| SCHEMBL5569838 | 0.69 | CYP17A1 (0.41) | CYP17A1CYP19A1 | |
| SCHEMBL5573331 | 0.69 | CYP17A1 (0.41) | CYP17A1IDO1TDO2 | |
| SCHEMBL1181751 | 0.68 | CYP17A1 (0.62) | CYP17A1RIPK1CYP19A1ALDH1A1CYP3A4 | |
| SCHEMBL1180209 | 0.67 | CYP17A1 (0.41) | CYP17A1CYP19A1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263615-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263615-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263615-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| CN-101326184-B | Bis-heterocyclic imidazolyl compounds | SPEEDEL EXPERIMENTA AG | 2011-11-23 | — | — | CN | disclosed |
| US-8008334-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| US-8008334-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| US-8008334-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| CN-102115473-A | Bis-heterocyclic imidazolyl compounds | SPEEDEL EXPERIMENTA AG | 2011-07-06 | — | — | CN | disclosed |
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | HEROLD PETER | 2011-02-03 | — | — | US | disclosed |
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | HEROLD PETER | 2011-02-03 | — | — | US | disclosed |
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | HEROLD PETER | 2011-02-03 | — | — | US | disclosed |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| CN-101326184-A | Bis-heterocyclic imidazolyl compounds | SPEEDEL EXPERIMENTA AG (CH) | 2008-12-17 | — | — | CN | disclosed |
| EP-1957489-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007065942-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065942-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | CYP11B1, CYP11B2, REN | CYP17A1 10/4885ROCK2 1445/4885HTR2C 2793/4885 |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | REN, CYP11B1, CYP11B2 | CYP17A1 13/4885ROCK2 1194/4885HTR2C 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.